Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
US11571459B2 · kind B2 · utility
0Cited by
101References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 2, 2018 |
| Grant date | Feb 7, 2023 |
| Priority date | — |
| Expiry date | May 30, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are surprising new methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on the surprising finding that human patients treated with bavituximab and checkpoint inhibitor antibodies have a statistically significant prolonged survival in controlled studies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.